Solid Biosciences Inc (SLDB) Actualités

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”...

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and...

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

- Duchenne: Dosed four patients in INSPIRE DUCHENNE clinical trial; SGT-003 has been well tolerated in all...

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CHARLESTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or...

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

- SGT-212 is the only full-length frataxin replacement gene therapy candidate targeting the CNS and cardiac...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”...

Solid Biosciences Added to the Nasdaq Biotechnology Index

CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

- Solid Biosciences to collaborate with Mayo Clinic’s genetic cardiology disease laboratory - - Solid to...

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHARLESTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”...

Solid Biosciences to Participate at Upcoming Investor Conferences

CHARLESTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or...